Palmatine chloride
Based on 9 publication(s) in Google Scholar
Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 10605-02-4
- Formula: C21H22ClNO4
- Molecular Weight:387.86
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Palmatine chloride
More- Phytomedicine. 2025 Sep 4:148:157233. [Abstract]
- J Ethnopharmacol. 2024 Jan 30;319(Pt 2):117238. [Abstract]
- Inflammation. 2025 Dec 20;49(1):11. [Abstract]
- Int Immunopharmacol. 2022 May:106:108583. [Abstract]
- Molecules. 2024 May 14;29(10):2304. [Abstract]
- Biol Res. 2020 Sep 14;53(1):39. [Abstract]
- Drug Dev Res. 2022 Nov;83(7):1613-1622. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Oxid Med Cell Longev. 2021 Mar 11:2021:6660193. [Abstract]
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
Cell Imaging/Staining
All Aurora Kinase Isoforms
MoreAll Parasite Isoforms
More
Biological Activity
|
IDO-1 3 μM (IC50, HEK 293-hIDO-1) |
IDO-1 157 μM (IC50, rhIDO-1) |
WNV NS2B-NS3 96 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| G-402 | GI50 |
83.14 μM
Compound: 3
|
Growth inhibition against human G402 cells after 48 hrs by MTT assay
Growth inhibition against human G402 cells after 48 hrs by MTT assay
|
[PMID: 21401114] |
| HCT-116 | IC50 |
>100 μM
Compound: Palmatine Chloride
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 28359045] |
| HepG2 | IC50 |
>100 μM
Compound: Palmatine Chloride
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 28359045] |
| HL-60 | IC50 |
>100 μM
Compound: Palmatine Chloride
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 28359045] |
| Huh-7 | CC50 |
>100 μM
Compound: GNF-Pf-4086
|
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
|
[PMID: 18579783] |
| KM12C | IC50 |
393 μM
Compound: B-11
|
Inhibition of cell proliferation of human KM12C cells incubated for 15 hrs by MTT assay
Inhibition of cell proliferation of human KM12C cells incubated for 15 hrs by MTT assay
|
[PMID: 32391701] |
| L02 | IC50 |
>100 μM
Compound: Palmatine Chloride
|
Cytotoxicity against human LO2 cells after 72 hrs by MTT assay
Cytotoxicity against human LO2 cells after 72 hrs by MTT assay
|
[PMID: 28359045] |
| SMMC-7721 | IC50 |
>100 μM
Compound: Palmatine Chloride
|
Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay
|
[PMID: 28359045] |
Palmatine (0-100 μM; 42 h) suppresses WNV with an EC50 value of 3.6 μM, and reduce the viral titers of DENV-2 and YFV with EC50 values of 26.4 μM and 7.3 μM, respectively[3].
Palmatine (0-1128 μM; 24-72 h) inhibits colon cancer cell proliferation[5].
Palmatine (0-704 μM; 24 h) reduces AURKA protein levels, induces G2/M phase arrest, and induces apoptosis in colon cancer cells via the mitochondrial associated pathway[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT-116, SW480, HT-29
-
Concentration:0, 88, 176, 352, and 704 μM (HCT-116, SW480); 0, 141, 282, 564, and 1128 μM (HT-29)
-
Incubation Time:24, 48 and 72 h
-
Result:Decreased cell viability in a dose-dependent manner.
-
Cell Line:HCT-116, SW480, HT-29
-
Concentration:100 nM for HCT-116, 500 nM for SW480 and HT-29
-
Incubation Time:24 h
-
Result:Promoted the expression of apoptosis markers such as P53 / P73, Caspase3, and Caspase9. Reduced AURKA protein levels. Increased cyt. c in the cytoplasm while reduced Bcl2 and Bcl-xl in a dose-dependent manner.
-
Cell Line:HCT-116, SW480
-
Concentration:88, 176, 352 and 704 μM
-
Incubation Time:24 h
-
Result:Induced G2/M phase arrest in a dose-dependent manner.
-
Cell Line:HCT-116, SW480
-
Concentration:88, 176, 352 and 704 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DSS- induced Colitis BALB/c mice model (8-week-old)[1]
-
Dosage:50 or 100 mg/kg
-
Administration:Orally, daily, for 7 days
-
Result:Ameliorated DSS-induced colitis and prevented infiltration of inflammatory cells; remarkably extended the colon length; significantly suppressed the colonic MPO activity. Decreased the levels of colonic inflammatory cytokines (TNF-α, IFN-γ, IL-1β, IL-6, IL-4 and IL-10); Protected mucosal integrity by modulating TJs protein and apoptosis proteins; Restored DSS-induced decreases of TJ protein ZO-1, ZO-2 and claudin-1; Reduced Bax expression and enhanced Bcl-2 expression at the dose of 100 mg/kg, prevented epithelial apoptosis and improved intestinal integrity. Prevented DSS-induced changes of gut microbiota in colitis mice.
-
Animal Model:Male ICR mice (20–22 g), D-galactosamine/lipopolysaccharide (GalN/LPS)-induced fulminant hepatic failure model[2]
-
Dosage:25, 50, 100, or 200 mg/kg
-
Administration:Intraperitoneal injection, 1 h before the GalN/LPS treatment
-
Result:Attenuated the mortality and serum aminotransferase activities increased by GalN/LPS. Prevented the increase of serum TNF-α and augmented that of serum IL-10. Decreased the TNF-a mRNA expression and increased the IL-10 mRNA expression. Attenuated the apoptosis of hepatocytes.
-
Animal Model:Swiss young male albino mice, with Scopolamine (HY-N0296)- and diazepam-induced amnesia model[4]
-
Dosage:0.1, 0.5, 1 mg/kg
-
Administration:Intraperitoneal injection, 10 days
-
Result:Significantly improved learning and memory of mice at 0.5 and 1 mg/kg and did not show any significant effect on locomotor activity of the mice. Significantly reversed scopolamine- and diazepam-induced amnesia in mice. Significantly reduced brain acetylcholinesterase activity of mice.
-
Animal Model:BALB/c-nude mice, HCT-116 xenograft model[5]
-
Dosage:33.75, 67.5 and 135 mg/kg
-
Administration:Oral administration, once a day for 26 days
-
Result:The tumor volume and weight of the treatment group were significantly reduced.
Chemical Information
-
CAS No. 10605-02-4
-
Appearance Solid
-
Molecular Weight 387.86
-
Formula C21H22ClNO4
-
Color Light yellow to yellow
-
SMILES
COC1=C(OC)C2=C[N+]3=C(C4=CC(OC)=C(OC)C=C4CC3)C=C2C=C1.[Cl-]
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Huang-Lian-Jie-Du decoction enhances Capecitabine-Oxaliplatin efficacy via Akkermansia muciniphila and CD8+ T cells in colorectal cancer. [Abstract]2025 Sep 4:148:157233. PMID: 40972261 -
J Ethnopharmacol
Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism. [Abstract]2024 Jan 30;319(Pt 2):117238. PMID: 37774895 -
Inflammation
Palmatine Attenuates Lipopolysaccharide-Induced Acute Lung Injury Via Suppression of NLRP3 Inflammasome Activation, Pyroptosis, and Metabolic Remodeling. [Abstract]2025 Dec 20;49(1):11. PMID: 41420798 -
Int Immunopharmacol
Palmatine attenuates the doxorubicin-induced inflammatory response, oxidative damage and cardiomyocyte apoptosis. [Abstract]2022 May:106:108583. PMID: 35151220 -
Molecules
Discovery of Nine Dipeptidyl Peptidase-4 Inhibitors from Coptis chinensis Using Virtual Screening, Bioactivity Evaluation, and Binding Studies. [Abstract]2024 May 14;29(10):2304. PMID: 38792165
Palmatine chloride purchased from MedChemExpress. Usage Cited in: Molecules. 2024 May 14;29(10):2304. [Abstract]
The DPP-4 inhibitory activity of Palmatine chloride (10-7-10-3 M), demeasured using dose-response curves.
-
Biol Res
2020 Sep 14;53(1):39. PMID: 32928312
Palmatine chloride purchased from MedChemExpress. Usage Cited in: Biol Res. 2020 Sep 14;53(1):39. [Abstract]
Palmatine chloride (PAL) (40 mg/kg; p.o.; once daily for 10 weeks) significantly decreased 2-h blood glucose level in HFD-fed SD rats.
Palmatine chloride purchased from MedChemExpress. Usage Cited in: Biol Res. 2020 Sep 14;53(1):39. [Abstract]
Palmatine chloride (PAL) (40 mg/kg; p.o.; once daily for 10 weeks) significantly decreased blood insulin levels in HFD-fed SD rats.
Palmatine chloride purchased from MedChemExpress. Usage Cited in: Biol Res. 2020 Sep 14;53(1):39. [Abstract]
Palmatine chloride (PAL) (40 mg/kg; p.o.; once daily for 10 weeks) restored the loss of β cell mass in HFD-fed SD rats, with predominantly increased area that stained positive for insulin.
Palmatine chloride purchased from MedChemExpress. Usage Cited in: Biol Res. 2020 Sep 14;53(1):39. [Abstract]
Palmatine chloride (PAL) (40 mg/kg; p.o.; once daily for 10 weeks) remarkably reduced the apoptotic rates in HFD-fed SD rats.
-
Drug Dev Res
Palmatine attenuates hepatocyte injury by promoting autophagy via the AMPK/mTOR pathway after alcoholic liver disease. [Abstract]2022 Nov;83(7):1613-1622. PMID: 35976121 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Oxid Med Cell Longev
Palmatine Protects against Cerebral Ischemia/Reperfusion Injury by Activation of the AMPK/Nrf2 Pathway. [Abstract]2021 Mar 11:2021:6660193. PMID: 33777318
Solvent & Solubility
DMSO : ≥ 32 mg/mL (82.50 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 5 mg/mL (12.89 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 2.5 mg/mL (6.45 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang XJ, et al. Palmatine ameliorated murine colitis by suppressing tryptophan metabolism and regulating gut microbiota.Pharmacol Res. 2018 Nov;137:34-46. [Content Brief]
[2]. Lee WC, et al. Palmatine attenuates D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice. Food Chem Toxicol. 2010 Jan;48(1):222-8. [Content Brief]
[3]. Jia F, et al. Identification of palmatine as an inhibitor of West Nile virus. Arch Virol. 2010 Aug;155(8):1325-9. [Content Brief]
[4]. Dhingra D, et al. Memory-enhancing activity of palmatine in mice using elevated plus maze and morris water maze. Adv Pharmacol Sci. 2012;2012:357368. [Content Brief]
[5]. Liu X, et al. Palmatine induces G2/M phase arrest and mitochondrial-associated pathway apoptosis in colon cancer cells by targeting AURKA. Biochem Pharmacol. 2020 May;175:113933. [Content Brief]
[6]. Long J, et al. Palmatine: A review of its pharmacology, toxicity and pharmacokinetics. Biochimie. 2019 Jul;162:176-184. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.5782 mL | 12.8912 mL | 25.7825 mL | 64.4562 mL |
| 5 mM | 0.5156 mL | 2.5782 mL | 5.1565 mL | 12.8912 mL | |
| 10 mM | 0.2578 mL | 1.2891 mL | 2.5782 mL | 6.4456 mL | |
| DMSO | 15 mM | 0.1719 mL | 0.8594 mL | 1.7188 mL | 4.2971 mL |
| 20 mM | 0.1289 mL | 0.6446 mL | 1.2891 mL | 3.2228 mL | |
| 25 mM | 0.1031 mL | 0.5156 mL | 1.0313 mL | 2.5782 mL | |
| 30 mM | 0.0859 mL | 0.4297 mL | 0.8594 mL | 2.1485 mL | |
| 40 mM | 0.0645 mL | 0.3223 mL | 0.6446 mL | 1.6114 mL | |
| 50 mM | 0.0516 mL | 0.2578 mL | 0.5156 mL | 1.2891 mL | |
| 60 mM | 0.0430 mL | 0.2149 mL | 0.4297 mL | 1.0743 mL | |
| 80 mM | 0.0322 mL | 0.1611 mL | 0.3223 mL | 0.8057 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.